JERSEY CITY, N.J., Oct. 2, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data, which further demonstrates the potential of ibrexafungerp as a treatment for invasive fungal infections, will be presented at IDWeek 2019, occurring October 2-6, 2019 in Washington DC, and TIMM-9,...
Category: News
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Oct. 01, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 51,750 ordinary shares of Nabriva Therapeutics as inducements to 8 newly-hired...
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
GENEVA and WALTHAM, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) — The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organization developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today jointly announced the initiation of...
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced its participation at the Cantor Fitzgerald...
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacterial pneumonia (CABP) DUBLIN, Ireland, Sept. 27, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious...
Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and CONTEPO™ (fosfomycin) clinical development programs will be presented at IDWeek 2019, to be held October 2-9...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that data from its NUZYRA (omadacycline) clinical and microbiology programs will be presented at IDWeek 2019, to be held October 2 through 6 in Washington, D.C.
Qpex Biopharma to Present its Anti-infective Portfolio at IDWeek 2019
SAN DIEGO, September 25, 2019 – Qpex Biopharma today announced scientific presentations on its investigational anti-infectives at the IDWeek 2019 Conference to be held October 2-6 in Washington, DC. Qpex scientists and external collaborators will be making the first public presentations on QPX9003, a next generation polymyxin antibiotic for multi-drug resistant Acinetobacter and Pseudomonas aeruginosa....
Summit Therapeutics to Host R&D Day 7 October 2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT...
Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
SAN DIEGO – September 24, 2019 – Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that preclinical data for fosmanogepix (APX001) will be presented at the upcoming scientific conferences IDWeek 2019 in Washington D.C. from October 2-6, 2019, and the 9th Congress on...